Alemtuzumab (Campath^®, Lemtrada^®) Monoklonaler Antikörper 21. 7. 2010; PubMed.gov; Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. http://www.ncbi.nlm.nih.gov/pubmed/20659956 9. 8. 2011; neurology.org; Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort http://www.neurology.org/gca?gca=neurology%3B77%2F6%2F573&allch=&submit=Go   7. 9. 2011: PubMed.gov; A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. http://www.ncbi.nlm.nih.gov/pubmed/21899662 „Conclusions:  Alemtuzumab effectively reduced relapse rates and improved clinical scores in patients with active relapsing- remitting multiple sclerosis not controlled by interferon therapy.“   24. 10. 2011; nature.com; Antibody offers hope for multiple sclerosis treatment http://www.nature.com/news/2011/111024/full/news.2011.609.html   17. 1. 2012; e-med forum; Ergebnisse der Phase-III-Studie zu Alemtuzumab bei Multipler Sklerose http://www.emed-ms.de/index.php?id=533&tt_news=1782 21. 3. 2012; PubMed.gov; Alemtuzumab more effective than interferon ß-1a at 5-year follow-up of CAMMS223 Clinical Trial. http://www.ncbi.nlm.nih.gov/pubmed/22442431 "CONCLUSIONS:  Through extended follow-up, alemtuzumab remained significantly more efficacious than IFNß-1a, with a safety profile consistent with previous reports.Classification of Evidence:This study provides Class III evidence that alemtuzumab is more effective than interferon ß-1a in reducing relapses and disability in patients with RRMS in a long-term follow-up of a rater-blinded, randomized clinical trial with 59.5% of patients participating in the extended follow-up period." 17. 8. 2012; Ärzte Zeitung.de; Leukämie-Arznei vom Markt genommen http://www.aerztezeitung.de/medizin/krankheiten/krebs/lymphome/default.aspx?sid=819675&cm_mmc=Newsletter-_- Newsletter-C-_-20120818-_-Lymphome/Leuk%C3%83%C2%A4mie 29. 8. 2012; Ärzte Zeitung.de; Hersteller sieht Versorgung gesichert http://www.aerztezeitung.de/medizin/krankheiten/neuro- psychiatrische_krankheiten/multiple_sklerose/default.aspx?sid=820626&cm_mmc=Newsletter-_-Newsletter-C-_-20120830-_- Multiple+Sklerose 20. 9. 2012; Ärzte Zeitung.de; Alemtuzumab - Rücknahme sorgt für Irritationen http://www.aerztezeitung.de/medizin/krankheiten/neuro- psychiatrische_krankheiten/multiple_sklerose/default.aspx?sid=822163&cm_mmc=Newsletter-_-Newsletter-C-_-20120921-_- Multiple+Sklerose 1. 11. 2012; aerzteblatt.de; Alemtuzumab: Zurückgezogenes Krebsmedikament bei multipler Sklerose wirksam http://www.aerzteblatt.de/nachrichten/52252 2. 11. 2012; pressetext.com; Multiple Sklerose: Krebsmedikament sehr wirksam http://www.pressetext.com/news/20121102007 31. 10. 2012; PubMed,gov; Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. http://www.ncbi.nlm.nih.gov/pubmed/23122650 „INTERPRETATION:  For patients with first-line treatment-refractory relapsing-remitting multiple sclerosis, alemtuzumab could be used to reduce relapse rates and sustained accumulation of disability. Suitable risk management strategies allow for early identification of alemtuzumab's main adverse effect of secondary autoimmunity.“ 8. 11. 2012; Neue Züricher Zeitung; Leukämie-Mittel wirkt auch gegen multiple Sklerose http://www.nzz.ch/wissen/wissenschaft/leukaemie-mittel-wirkt-auch-gegen-multiple-sklerose-1.17769949 Feb. 2013; PubMed.gov; Alemtuzumab Treatment of Multiple Sclerosis. http://www.ncbi.nlm.nih.gov/pubmed/23709214 „Its use requires careful monitoring so that potentially serious side effects can be treated early and effectively.“ 23. 6. 2013; PubMed.gov; [Alemtuzumab for relapsing-remitting multiple sclerosis : Results of two randomized controlled phase III studies.] http://www.ncbi.nlm.nih.gov/pubmed/23793409 „Taken together these studies confirm the high anti-inflammatory efficacy of alemtuzumab and hence provide the first evidence of superiority of a monotherapy in direct comparison to standard disease-modifying treatment in two phase III trials in relapsing-remitting MS. These data in the context of the mode of action of alemtuzumab provide evidence for the relevance of immune cells, especially T cells, in the pathophysiology of MS. Experience with long-term effects of alemtuzumab, e.g. from the phase II extension trial as well as the side effect profile argue 19. 9. 2013; amsel.de; Breites Therapiespektrum bei Alemtuzumab überrascht http://www.amsel.de/multiple-sklerose-news/medizin/Breites-Therapiespektrum-bei-Alemtuzumab-ueberrascht_4901 29. 10. 2013; PubMed.gov: Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients with Relapsing- Remitting Multiple Sclerosis. http://www.ncbi.nlm.nih.gov/pubmed/24170099 13. 11. 2013; frontal21; Neue Märkte für alte Medikamente - Die Methoden der Pharmafirmen http://www.zdf.de/Frontal-21/Sendung-vom-12.-November-30572142.html 3. 1. 2014; amsel.de; Vorerst keine Zulassung für Alemtuzumab in USA http://www.amsel.de/multiple-sklerose-news/medizin/Vorerst-keine-Zulassung-fuer-Alemtuzumab-in-USA_4988 3. 2. 2014; currado.de; EMA lässt Alemtuzumab für die MS-Therapie zu http://www.curado.de/alemtuzumab-ms-therapie-zu-27398/ 7. 3. 2014; PubMed.gov; Alemtuzumab: A Review of Its Use in Patients with Relapsing Multiple Sclerosis. http://www.ncbi.nlm.nih.gov/pubmed/24604792 „There was an increased risk of autoimmunity and infection associated with alemtuzumab in these trials; while these adverse events were generally mild to moderate, some were severe. Alemtuzumab is a highly convenient treatment, requiring hospital attendance for an intravenous infusion for a handful of days on two consecutive years, with no treatment required in between; however, this convenience is counterbalanced by the need for regular monitoring for the increased risk of autoimmunity. More investigation is required before final conclusions can be drawn on the correct placement of alemtuzumab in multiple sclerosis treatment; however, it is of a certainty a welcome addition to the treatment options for these patients.“ 25. 4. 2012; handeldblatt.com; Sanofi meldet Erfolg bei MS-Medikament http://www.handelsblatt.com/unternehmen/industrie/multiple-sklerose-sanofi-meldet-erfolg-bei-ms-medikament/6551924.html 20. 11. 2013; e-med forum; FDA-Expertengremium unterstützt Zulassung des MS-Medikaments Lemtrada in den USA http://www.emed-ms.de/index.php?id=533&tt_news=2151 30. 12. 2013, börsen-ticker; Sanofi erhält in USA vorerst keine Zulassung für Multiple-Sklerose-Medikament http://www.cash.ch/news/boersenticker/rss/sanofi_erhaelt_in_usa_vorerst_keine_zulassung_fuer_multiplesklerosemedikament -3157421-450 16. 5. 1014; 3sat.de; Alte Arznei, neuer Preis - Pharmafirma vermarktet Leukämiemedikament neu http://www.3sat.de/page/?source=/nano/medizin/176679/index.html „Weil der französische Pharmakonzern Sanofi sein einstiges Leukämiemittel Lemtrada jetzt für Multiple-Sklerose-Patienten vermarktet, kostet der Wirkstoff das 40-Fache.“ Anm. des Autors dieser Home page: „Bravo...“ 21 .5. 2014; PubMed.gov; Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. http://www.ncbi.nlm.nih.gov/pubmed/24849515 „CONCLUSIONS: Alemtuzumab is associated with disease stabilisation in the majority of patients with highly active RRMS over an average seven-year follow-up. No new safety concerns arose over this extended follow-up.“ “Wenn jemand überzeugt ist, dass er aus der Kirche austreten muss und das aus Angst vor Repressionsmaßnahmen nicht macht, begeht er eine Sünde. Gewissensfreiheit ist das Absolute.” Thomas von Aquin Zur Medikamenten-Übersicht http://georgieff.at/